Literature DB >> 33757158

Transcranial Alternating Current Stimulation Reduces Network Hypersynchrony and Persistent Vertigo.

Sangtae Ahn1,2,3,4, Diamond Gleghorn5, Benjamin Doudican6, Flavio Fröhlich3,4,7,8,9,10, Yoon-Hee Cha6,11.   

Abstract

OBJECTIVES: Persistent oscillating vertigo that occurs after entrainment to periodic motion is known as Mal de Débarquement Syndrome (MdDS). Down-modulation of this oscillating vertigo is associated with reduction in long-range resting-state functional connectivity between fronto-parieto-occipital regions. In order to determine the association between this oscillating vertigo and hypersynchrony as measured by the auditory steady-state response (ASSR), we investigated the differences in ASSR between individuals with MdDS and healthy controls as well as the change in ASSR in individuals with MdDS before and after treatment with transcranial alternating current stimulation (tACS).
MATERIALS AND METHODS: Individuals with treatment refractory MdDS lasting at least six months received single administrations of fronto-parieto-occipital tACS in an "n-of-1" double-blind randomized design: alpha-frequency in-phase, alpha-frequency antiphase, and gamma frequency antiphase control. The treatment protocol that led to the most acute reduction in symptoms and improved balance was administered for 10-12 sessions given over three days (each session 20-min at 2-4 mA).
RESULTS: Twenty-four individuals with MdDS participated (mean age 53.0 ± 11.8 years [range: 22-66 years, median: 57.0 years]; mean duration of illness 38.6 ± 53.4 months [range: 6-240 months, median: 18.0 months]). Individuals with MdDS had elevated ASSR compared to healthy controls at baseline (t11  = 5.95, p < 0.001). There was a significant decrease in the 40 Hz-ASSR response between responders compared to nonresponders to tACS (t-test, t15  = -2.26, p = 0.04). Both in-phase and anti-phase alpha tACS lead to symptom improvement but only antiphase alpha-tACS led to a significant decrease of 40 Hz-ASSR (t-test, t12  = -9.6, p < 0.001).
CONCLUSIONS: Our findings suggest that tACS has the potential to reduce network-level hypersynchrony and pathological susceptibility to entrainment by sensory input. To the best of our knowledge, this is the first successful demonstration of desynchronization by noninvasive brain stimulation leading to reduced vertigo. Other disease states associated with pathological functional coupling of neuronal networks may similarly benefit from this novel approach.
© 2021 International Neuromodulation Society.

Entities:  

Keywords:  Auditory steady-state response; Mal de Débarquement Syndrome; persistent oscillating vertigo; transcranial alternating current stimulation

Mesh:

Year:  2021        PMID: 33757158      PMCID: PMC8491986          DOI: 10.1111/ner.13389

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  35 in total

1.  Mechanism of graded persistent cellular activity of entorhinal cortex layer v neurons.

Authors:  Erik Fransén; Babak Tahvildari; Alexei V Egorov; Michael E Hasselmo; Angel A Alonso
Journal:  Neuron       Date:  2006-03-02       Impact factor: 17.173

2.  Double-Blind Sham-Controlled Crossover Trial of Repetitive Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome.

Authors:  Yoon-Hee Cha; Choi Deblieck; Allan D Wu
Journal:  Otol Neurotol       Date:  2016-07       Impact factor: 2.311

Review 3.  Mal de debarquement.

Authors:  Yoon-Hee Cha
Journal:  Semin Neurol       Date:  2009-10-15       Impact factor: 3.420

4.  Clinical features and associated syndromes of mal de debarquement.

Authors:  Yoon-Hee Cha; Jae Brodsky; Gail Ishiyama; Chiara Sabatti; Robert W Baloh
Journal:  J Neurol       Date:  2008-05-30       Impact factor: 4.849

5.  Alpha Power Increase After Transcranial Alternating Current Stimulation at Alpha Frequency (α-tACS) Reflects Plastic Changes Rather Than Entrainment.

Authors:  Alexandra Vossen; Joachim Gross; Gregor Thut
Journal:  Brain Stimul       Date:  2014-12-20       Impact factor: 8.955

6.  40-Hz ASSR fusion classification system for observing sleep patterns.

Authors:  Gulzar A Khuwaja; Sahar Javaher Haghighi; Dimitrios Hatzinakos
Journal:  EURASIP J Bioinform Syst Biol       Date:  2015-02-05

7.  Electrophysiological Signatures of Intrinsic Functional Connectivity Related to rTMS Treatment for Mal de Debarquement Syndrome.

Authors:  Yoon-Hee Cha; Guofa Shou; Diamond Gleghorn; Benjamin C Doudican; Han Yuan; Lei Ding
Journal:  Brain Topogr       Date:  2018-08-11       Impact factor: 3.020

8.  Brain-derived neurotrophic factor (BDNF) polymorphism may influence the efficacy of tACS to modulate neural oscillations.

Authors:  Justin Riddle; Trevor McPherson; Alana K Atkins; Christopher P Walker; Sangtae Ahn; Flavio Frohlich
Journal:  Brain Stimul       Date:  2020-04-21       Impact factor: 8.955

Review 9.  Synchronization and desynchronization in epilepsy: controversies and hypotheses.

Authors:  Premysl Jiruska; Marco de Curtis; John G R Jefferys; Catherine A Schevon; Steven J Schiff; Kaspar Schindler
Journal:  J Physiol       Date:  2012-11-26       Impact factor: 5.182

10.  Comprehensive Clinical Profile of Mal De Debarquement Syndrome.

Authors:  Yoon-Hee Cha; Yong Yan Cui; Robert W Baloh
Journal:  Front Neurol       Date:  2018-05-07       Impact factor: 4.003

View more
  3 in total

1.  Treatment of Gravitational Pulling Sensation in Patients With Mal de Debarquement Syndrome (MdDS): A Model-Based Approach.

Authors:  Sergei B Yakushin; Theodore Raphan; Catherine Cho
Journal:  Front Integr Neurosci       Date:  2022-05-23

2.  Double-blind randomized N-of-1 trial of transcranial alternating current stimulation for mal de débarquement syndrome.

Authors:  Yoon-Hee Cha; Diamond Gleghorn; Benjamin Chipper Doudican
Journal:  PLoS One       Date:  2022-02-04       Impact factor: 3.240

3.  Remotely Monitored Home-Based Neuromodulation With Transcranial Alternating Current Stimulation (tACS) for Mal de Débarquement Syndrome.

Authors:  Yoon-Hee Cha; Jeff Riley; Diamond Gleghorn; Benjamin Doudican
Journal:  Front Neurol       Date:  2021-12-09       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.